PubRank

M V Relling

Author PubWeight™ 149.20‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Pharmacogenomics: translating functional genomics into rational therapeutics. Science 1999 8.25
2 Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance. Ann Intern Med 1997 4.13
3 Nomenclature for N-acetyltransferases. Pharmacogenetics 1995 3.59
4 Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia. N Engl J Med 1998 2.59
5 Pharmacogenomics and individualized medicine: translating science into practice. Clin Pharmacol Ther 2012 2.48
6 The role of inherited TPMT and COMT genetic variation in cisplatin-induced ototoxicity in children with cancer. Clin Pharmacol Ther 2013 2.40
7 The Pharmacogenomics Research Network Translational Pharmacogenetics Program: overcoming challenges of real-world implementation. Clin Pharmacol Ther 2013 2.39
8 Human granulocyte colony-stimulating factor after induction chemotherapy in children with acute lymphoblastic leukemia. N Engl J Med 1997 2.38
9 Long-term results of St Jude Total Therapy Studies 11, 12, 13A, 13B, and 14 for childhood acute lymphoblastic leukemia. Leukemia 2009 2.24
10 The pharmacogenetics research network: from SNP discovery to clinical drug response. Clin Pharmacol Ther 2007 2.18
11 A clinician-driven automated system for integration of pharmacogenetic interpretations into an electronic medical record. Clin Pharmacol Ther 2012 2.12
12 Long-term results of Total Therapy studies 11, 12 and 13A for childhood acute lymphoblastic leukemia at St Jude Children's Research Hospital. Leukemia 2000 1.94
13 Traumatic lumbar puncture at diagnosis adversely affects outcome in childhood acute lymphoblastic leukemia. Blood 2000 1.89
14 Preponderance of thiopurine S-methyltransferase deficiency and heterozygosity among patients intolerant to mercaptopurine or azathioprine. J Clin Oncol 2001 1.82
15 Genetic polymorphism of inosine triphosphate pyrophosphatase is a determinant of mercaptopurine metabolism and toxicity during treatment for acute lymphoblastic leukemia. Clin Pharmacol Ther 2008 1.82
16 P-glycoprotein: a major determinant of rifampicin-inducible expression of cytochrome P4503A in mice and humans. Proc Natl Acad Sci U S A 1996 1.65
17 Concordance of DMET plus genotyping results with those of orthogonal genotyping methods. Clin Pharmacol Ther 2012 1.62
18 Early intensification of intrathecal chemotherapy virtually eliminates central nervous system relapse in children with acute lymphoblastic leukemia. Blood 1998 1.60
19 Topoisomerase II inhibitor-related acute myeloid leukaemia. Br J Haematol 2000 1.57
20 Rationale and design of Total Therapy Study XV for newly diagnosed childhood acute lymphoblastic leukemia. Ann Hematol 2004 1.57
21 Relationship between cytotoxicity and site-specific DNA recombination after in vitro exposure of leukemia cells to etoposide. J Natl Cancer Inst 1996 1.54
22 Genetic polymorphism of thiopurine S-methyltransferase: clinical importance and molecular mechanisms. Pharmacogenetics 1996 1.50
23 Accumulation of methotrexate polyglutamates in lymphoblasts is a determinant of antileukemic effects in vivo. A rationale for high-dose methotrexate. J Clin Invest 1996 1.49
24 Genetic polymorphism of thiopurine methyltransferase and its clinical relevance for childhood acute lymphoblastic leukemia. Leukemia 2000 1.48
25 Polymorphism of the thiopurine S-methyltransferase gene in African-Americans. Hum Mol Genet 1999 1.40
26 Simultaneous characterization of glutathione S-transferase M1 and T1 polymorphisms by polymerase chain reaction in American whites and blacks. Pharmacogenetics 1996 1.38
27 Recombinant urate oxidase for the prophylaxis or treatment of hyperuricemia in patients With leukemia or lymphoma. J Clin Oncol 2001 1.38
28 Hypersensitivity or development of antibodies to asparaginase does not impact treatment outcome of childhood acute lymphoblastic leukemia. J Clin Oncol 2000 1.37
29 A single point mutation leading to loss of catalytic activity in human thiopurine S-methyltransferase. Proc Natl Acad Sci U S A 1995 1.36
30 ARID5B SNP rs10821936 is associated with risk of childhood acute lymphoblastic leukemia in blacks and contributes to racial differences in leukemia incidence. Leukemia 2010 1.34
31 Clinical pharmacokinetics of paclitaxel. Clin Pharmacokinet 1994 1.32
32 Saturable pharmacokinetics and paclitaxel pharmacodynamics in children with solid tumors. J Clin Oncol 1994 1.29
33 Blast cell methotrexate-polyglutamate accumulation in vivo differs by lineage, ploidy, and methotrexate dose in acute lymphoblastic leukemia. J Clin Invest 1994 1.29
34 Differences in constitutive and post-methotrexate folylpolyglutamate synthetase activity in B-lineage and T-lineage leukemia. Blood 1994 1.29
35 Polymorphic thiopurine methyltransferase in erythrocytes is indicative of activity in leukemic blasts from children with acute lymphoblastic leukemia. Blood 1995 1.29
36 Variability in human cytochrome P450 paclitaxel metabolism. J Pharmacol Exp Ther 1995 1.23
37 Differences in folylpolyglutamate synthetase and dihydrofolate reductase expression in human B-lineage versus T-lineage leukemic lymphoblasts: mechanisms for lineage differences in methotrexate polyglutamylation and cytotoxicity. Mol Pharmacol 1997 1.23
38 Higher frequency of glutathione S-transferase deletions in black children with acute lymphoblastic leukemia. Blood 1997 1.18
39 Urate oxidase in prevention and treatment of hyperuricemia associated with lymphoid malignancies. Leukemia 1997 1.18
40 Evaluation of immunologic crossreaction of antiasparaginase antibodies in acute lymphoblastic leukemia (ALL) and lymphoma patients. Leukemia 2003 1.18
41 Differing contribution of thiopurine methyltransferase to mercaptopurine versus thioguanine effects in human leukemic cells. Cancer Res 2001 1.15
42 Genetic variations in GRIA1 on chromosome 5q33 related to asparaginase hypersensitivity. Clin Pharmacol Ther 2010 1.15
43 Functional characterization of liver enhancers that regulate drug-associated transporters. Clin Pharmacol Ther 2011 1.14
44 Using HapMap tools in pharmacogenomic discovery: the thiopurine methyltransferase polymorphism. Clin Pharmacol Ther 2007 1.11
45 Pharmacokinetics and toxicity of methotrexate in children with Down syndrome and acute lymphocytic leukemia. J Pediatr 1987 1.10
46 Clinical utility and implications of asparaginase antibodies in acute lymphoblastic leukemia. Leukemia 2012 1.10
47 Reduced folate carrier expression in acute lymphoblastic leukemia: a mechanism for ploidy but not lineage differences in methotrexate accumulation. Blood 1999 1.09
48 ETV6-RUNX1-positive childhood acute lymphoblastic leukemia: improved outcome with contemporary therapy. Leukemia 2011 1.08
49 Increased risk for CNS relapse in pre-B cell leukemia with the t(1;19)/TCF3-PBX1. Leukemia 2009 1.07
50 Magnetic resonance imaging detection of avascular necrosis of the bone in children receiving intensive prednisone therapy for acute lymphoblastic leukemia or non-Hodgkin lymphoma. Leukemia 2001 1.05
51 Genome scan implicates adhesion biological pathways in secondary leukemia. Leukemia 2007 1.04
52 Altered expression of hepatic cytochromes P-450 in mice deficient in one or more mdr1 genes. Mol Pharmacol 2000 1.04
53 Assay of 6-mercaptopurine and its metabolites in patient plasma by high-performance liquid chromatography with diode-array detection. J Chromatogr B Biomed Sci Appl 1999 1.04
54 A genome-wide approach identifies that the aspartate metabolism pathway contributes to asparaginase sensitivity. Leukemia 2010 1.03
55 Age-related differences in hepatic drug clearance in children: studies with lorazepam and antipyrine. Clin Pharmacol Ther 1991 1.02
56 Comparison of native E. coli and PEG asparaginase pharmacokinetics and pharmacodynamics in pediatric acute lymphoblastic leukemia. Clin Pharmacol Ther 2009 1.01
57 Identification of a new variant CYP2D6 allele with a single base deletion in exon 3 and its association with the poor metabolizer phenotype. Hum Mol Genet 1994 1.01
58 Transient encephalopathy following high-dose methotrexate treatment in childhood acute lymphoblastic leukemia. Leukemia 1998 1.01
59 L-asparaginase may potentiate the leukemogenic effect of the epipodophyllotoxins. Leukemia 1995 1.00
60 Asparaginase pharmacodynamics differ by formulation among children with newly diagnosed acute lymphoblastic leukemia. Leukemia 2004 1.00
61 Sex differences in prognosis for children with acute lymphoblastic leukemia. J Clin Oncol 1999 1.00
62 Anti-asparaginase antibodies following E. coli asparaginase therapy in pediatric acute lymphoblastic leukemia. Leukemia 1998 1.00
63 Phase I trial of paclitaxel in children with refractory solid tumors: a Pediatric Oncology Group Study. J Clin Oncol 1993 0.99
64 Clinical pharmacology of cancer chemotherapy in children. Pediatr Clin North Am 1989 0.98
65 Glutathione S-transferase genotypes in children who develop treatment-related acute myeloid malignancies. Leukemia 2000 0.98
66 Genetic basis for a lower prevalence of deficient CYP2D6 oxidative drug metabolism phenotypes in black Americans. J Clin Invest 1993 0.98
67 Clinical pharmacokinetics-pharmacodynamics of anticancer drugs. Clin Pharmacokinet 1989 0.98
68 Epipodophyllotoxin-related acute myeloid leukemia: a study of 35 cases. Leukemia 1995 0.97
69 ELISA to evaluate plasma anti-asparaginase IgG concentrations in patients with acute lymphoblastic leukemia. J Immunol Methods 2000 0.94
70 Genome-wide approach to identify risk factors for therapy-related myeloid leukemia. Leukemia 2006 0.94
71 Dextromethorphan and caffeine as probes for simultaneous determination of debrisoquin-oxidation and N-acetylation phenotypes in children. Clin Pharmacol Ther 1989 0.94
72 Simultaneous administration of multiple model substrates to assess hepatic drug clearance. Clin Pharmacol Ther 1987 0.93
73 Reappraisal of the clinical and biologic significance of myeloid-associated antigen expression in childhood acute lymphoblastic leukemia. J Clin Oncol 1998 0.92
74 Thioguanine substitution alters DNA cleavage mediated by topoisomerase II. FASEB J 2000 0.92
75 Human cytochrome P450 maximal activities in pediatric versus adult liver. Drug Metab Dispos 2000 0.91
76 Individualized methotrexate dosing in children with relapsed acute lymphoblastic leukemia. Leukemia 2000 0.91
77 Molecular emergence of acute myeloid leukemia during treatment for acute lymphoblastic leukemia. Proc Natl Acad Sci U S A 2001 0.91
78 Hepatic drug clearance in children: studies with indocyanine green as a model substrate. J Pharm Sci 1989 0.91
79 Calcium and cholecalciferol supplementation provides no added benefit to nutritional counseling to improve bone mineral density in survivors of childhood acute lymphoblastic leukemia (ALL). Pediatr Blood Cancer 2014 0.90
80 Cerebrospinal fluid asparagine concentrations after Escherichia coli asparaginase in children with acute lymphoblastic leukemia. J Clin Oncol 1999 0.90
81 Functional characterization of ABCC2 promoter polymorphisms and allele-specific expression. Pharmacogenomics J 2012 0.89
82 Drug-induced hemorrhagic cystitis. Clin Pharm 1986 0.87
83 Isolation of a human thiopurine S-methyltransferase (TPMT) complementary DNA with a single nucleotide transition A719G (TPMT*3C) and its association with loss of TPMT protein and catalytic activity in humans. Clin Pharmacol Ther 1998 0.86
84 International Childhood Acute Lymphoblastic Leukemia Workshop: Sausalito, CA, 30 November-1 December 2000. Leukemia 2001 0.85
85 Disposition of antineoplastic agents in the very young child. Br J Cancer Suppl 1992 0.85
86 Pharmacokinetics of anticancer drugs in children. Clin Pharmacokinet 1987 0.84
87 Clinical pharmacokinetics and pharmacodynamics of anticancer drugs in children. Semin Oncol 1993 0.84
88 Overt testicular disease at diagnosis of childhood acute lymphoblastic leukemia: lack of therapeutic role of local irradiation. Leukemia 2005 0.84
89 CYP1A2 and CYP2D6 4-hydroxylate propranolol and both reactions exhibit racial differences. J Pharmacol Exp Ther 2000 0.84
90 Effect of methotrexate polyglutamates on thioguanine nucleotide concentrations during continuation therapy of acute lymphoblastic leukemia with mercaptopurine. Leukemia 2002 0.82
91 Simultaneous quantitation of etoposide and its catechol metabolite in human plasma using high-performance liquid chromatography with electrochemical detection. J Chromatogr B Biomed Sci Appl 1999 0.82
92 Concordance of P450 2D6 (debrisoquine hydroxylase) phenotype and genotype: inability of dextromethorphan metabolic ratio to discriminate reliably heterozygous and homozygous extensive metabolizers. Pharmacogenetics 1991 0.82
93 Creation of polarized cells coexpressing CYP3A4, NADPH cytochrome P450 reductase and MDR1/P-glycoprotein. Pharm Res 2000 0.82
94 Clinical implementation of pharmacogenetics: more than one gene at a time. Clin Pharmacol Ther 2013 0.82
95 Etoposide causes illegitimate V(D)J recombination in human lymphoid leukemic cells. Blood 1996 0.82
96 Etoposide sensitivity does not predict MLL rearrangements or risk of therapy-related acute myeloid leukemia. Clin Pharmacol Ther 2008 0.82
97 Allopurinol inhibits de novo purine synthesis in lymphoblasts of children with acute lymphoblastic leukemia. Leukemia 1996 0.82
98 Clinical pharmacodynamic studies of high-dose methotrexate in acute lymphocytic leukemia. NCI Monogr 1987 0.81
99 Low frequency of TEL-AML1 in relapsed acute lymphoblastic leukemia supports a favorable prognosis for this genetic subgroup. Leukemia 1999 0.81
100 The frequency of illegitimate V(D)J recombinase-mediated mutations in children treated with etoposide-containing antileukemic therapy. Mutat Res 1998 0.81
101 Successful challenges using native E. coli asparaginase after hypersensitivity reactions to PEGylated E. coli asparaginase. Cancer Chemother Pharmacol 2014 0.81
102 Pharmacokinetics of paclitaxel in an anephric patient. Cancer Chemother Pharmacol 1999 0.81
103 Individualized dosages of chemotherapy as a strategy to improve response for acute lymphocytic leukemia. Semin Hematol 1991 0.80
104 Xbal 16- plus 9-kilobase DNA restriction fragments identify a mutant allele for debrisoquin hydroxylase: report of a family study. Mol Pharmacol 1990 0.80
105 Concept of maximum tolerated systemic exposure and its application to phase I-II studies of anticancer drugs. Med Pediatr Oncol 1991 0.80
106 Pharmacogenetics: call to action. Clin Pharmacol Ther 2011 0.80
107 Low-dose oral etoposide-based induction regimen for children with acute lymphoblastic leukemia in first bone marrow relapse. Leukemia 2004 0.80
108 Genetic studies of childhood acute lymphoblastic leukemia with emphasis on p16, MLL, and ETV6 gene abnormalities: results of St Jude Total Therapy Study XII. Leukemia 1997 0.79
109 PharmGKB update: II. CYP3A5, cytochrome P450, family 3, subfamily A, polypeptide 5. Pharmacol Rev 2004 0.79
110 Increased teniposide clearance with concomitant anticonvulsant therapy. J Clin Oncol 1992 0.79
111 Anticancer therapy as a pediatric pharmacodynamic paradigm. Dev Pharmacol Ther 1989 0.79
112 Clinical and biological characteristics of acute lymphocytic leukemia in children with Down syndrome. Am J Med Genet Suppl 1990 0.78
113 Phenotypic debrisoquine 4-hydroxylase activity among extensive metabolizers is unrelated to genotype as determined by the Xba-I restriction fragment length polymorphism. Br J Clin Pharmacol 1991 0.78
114 Phase I targeted systemic exposure study of paclitaxel in children with refractory acute leukemias. Clin Cancer Res 1999 0.78
115 Mercaptopurine vs thioguanine for the treatment of acute lymphoblastic leukemia. Leuk Res 1994 0.78
116 Pharmacokinetics and pharmacodynamics of 21-day continuous oral etoposide in pediatric patients with solid tumors. Clin Pharmacol Ther 1995 0.78
117 A human lymphoid leukemia cell line with a V(D)J recombinase-mediated deletion of hprt. Mutat Res 1998 0.77
118 Promoter polymorphisms in the β-2 adrenergic receptor are associated with drug-induced gene expression changes and response in acute lymphoblastic leukemia. Clin Pharmacol Ther 2010 0.76
119 Automated high-performance liquid chromatographic assay for the determination of 7-ethoxycoumarin and umbelliferone. J Chromatogr 1992 0.76
120 Infants with acute lymphoblastic leukemia: no evidence for high methotrexate resistance. Leukemia 2002 0.76
121 Gazing into a crystal ball-cancer therapy in the post-genomic era. Nat Med 2001 0.76
122 Does pharmacokinetic variability influence the efficacy of high-dose methotrexate for the treatment of children with acute lymphoblastic leukemia: what can we learn from small studies? Leuk Res 1997 0.75
123 The effect of atovaquone on etoposide pharmacokinetics in children with acute lymphoblastic leukemia. Cancer Chemother Pharmacol 2001 0.75
124 Intrapatient variation in aminoglycoside disposition in cystic fibrosis. Clin Pharm 1987 0.75
125 Choosing a sunscreen. Ariz Med 1983 0.75
126 Differences in teniposide disposition and pharmacodynamics in patients with newly diagnosed and relapsed acute lymphocytic leukemia. J Pharmacol Exp Ther 1992 0.75
127 Hepatic drug clearance in children with leukemia: changes in clearance of model substrates during remission-induction therapy. Clin Pharmacol Ther 1987 0.75
128 CYP2D6, N-acetylation, and xanthine oxidase activity in cystic fibrosis. Pharmacotherapy 1997 0.75
129 Defining the optimal dosage of methotrexate for childhood acute lymphoblastic leukemia. New insights from the lab and clinic. Adv Exp Med Biol 1999 0.75
130 MLL methylation is not likely a common mechanism for therapy-related AML. Leukemia 2005 0.75
131 Variability in teniposide plasma protein binding is correlated with serum albumin concentrations. Pharmacotherapy 1992 0.75
132 Cytochrome P450 2D6 and glutathione S-transferase genotype in sudden infant death syndrome. J Paediatr Child Health 1997 0.75
133 Stability of etoposide solution for oral use. Am J Hosp Pharm 1992 0.75
134 Chemotherapy induced nausea and emesis in pediatric cancer patients: external validity of child and parent emesis ratings. J Dev Behav Pediatr 1993 0.75
135 Phase I study of flavone acetic acid (NSC 347512, LM975) in patients with pediatric malignant solid tumors. Am J Clin Oncol 1991 0.75